You are currently browsing the archives for 25 June 2018.
Displaying 1 entry.

Today reported outcomes for the fourth quarter and full yr of its fiscal yr ended June 30.

Array continues to engage in discussions to identify a partner for Europe for both binimetinib and encorafenib and will provide further improvements when appropriate. This mixture therapy showed an adverse event profile generally consistent with current understanding of the security profiles of dacarbazine and selumetinib. A full evaluation of the info is definitely ongoing. AstraZeneca and Array usually do not believe the results out of this trial inform the outcome of the ongoing selumetinib registration studies in second-collection KRAS-mutant non-little cell lung malignancy , thyroid tumor or neurofibromatosis 1 .